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FACTORS ASSOCIATED WITH PRESCRIPTION 
CLAIMS FOR BLOOD GLUCOSE TEST STRIPS 
AMONG FEE-FOR-SERVICE NEW MEXICO 
MEDICAID PATIENTS
Cordova CJ, Shah BM, Dodd MA, Gupchup GV
The University of New Mexico, Albuquerque, NM, USA
OBJECTIVE: Continuous blood glucose monitoring
which requires the use of blood glucose test strips (BGTS)
is essential for diabetes management. The objective of
this study was to identify predictors of claims for BGTS
submitted to the New Mexico Medicaid fee-for-service
(NMMFFS) program. METHODS: Patients with pre-
scription claims for insulin or oral diabetic medications
between December 1, 1999 and November 30, 2000
were identified from the NMMFFS claims database. It
was determined if these patients had claims for BGTS. In-
formation on demographic predictors including age, gen-
der, race/ethnicity, insulin use, and area of residence (ru-
ral, urban, intermediate) were extracted. A forward
stepwise logistic regression analysis using the likelihood-
ratio (LR) test, was performed to identify significant pre-
dictors of claims for BGTS. RESULTS: A total of 5636
diabetic patients, mean age 65.93 (SD  17.25), were
identified. Of these, 38.6% (n  2178) had claims for
BGTS. About 70% (n  3974) were female, 45.1% (n 
2543) had claims for insulin, and 38.8% (n  2185) re-
sided in an urban area. Additionally, there were 42.7%
(n  2408) non-Hispanic whites, 30.8% (n  1738) His-
panics, and 9.2% (n  519) American Indians. The logis-
tic regression results indicated that younger patients (OR
 0.97, 95% CI  0.97–0.98) and patients with claims
for insulin (OR  1.88, 95%CI  1.68–2.11) were more
likely to have claims for BGTS. However, males (OR 
0.64, 95% CI  0.56–0.73), patients who lived in inter-
mediate areas (OR  0.74, 95% CI  0.65–0.83), non-
Hispanic whites (OR  0.78, 95% CI  0.67–0.91), His-
panics (OR  0.63, 95% CI  0.53–0.75) and American
Indians (OR  0.40, 95% CI  0.32–0.51) were all less
likely to have claims for BGTS. CONCLUSIONS: Elderly
patients who are female, non-insulin users, non-Hispanic
white, Hispanic or American Indian and live in interme-
diate areas are less likely to have claims for strips. There-
fore, educational interventions are needed to increase
claims for BGTS in these patients, thus improving blood
glucose monitoring.
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COST-EFFECTIVENESS ANALYSIS OF A 
MULTIDISCIPLINARY DIABETES CARE CLINIC
Yokoyama KK, Griffin KC, Godley PJ, Cryar AK,
Woodward BW
Scott & White Memorial Hospital, Temple, TX, USA
OBJECTIVES: Diabetes affects more than 15.7 million
people in the United States, resulting in an estimated an-
nual cost of $98 billion (1997). With numerous compli-
cations, including heart disease, retinopathy, nephropa-
thy, and neuropathy, contributing to the direct and
indirect costs of diabetes, control is vital. A cost-effective-
ness analysis was performed to compare health care re-
source utilization related to diabetes care incurred by
health plan patients. METHODS: Subjects were enrolled
in the Diabetes Care Clinic (DCC) for at least one year
and were members of the health plan for one year prior
to enrollment. Pharmacy and medical claims data from
1997–2000 were analyzed to identify diabetes-related
charges incurred one year pre- and post-enrollment in the
DCC. Charges were used to estimate costs and were ad-
justed to year 2000 dollars at a rate of inflation of 3%.
Using the electronic medical record and clinic charts, he-
moglobin A1c (HgbA1c), cholesterol profile, microalbu-
minuria, and blood pressure were evaluated. RESULTS:
23 diabetic patients met the inclusion criteria. These pa-
tients were mostly Type 2 diabetics (91%), female
(65%), and Caucasian (70%). The mean age was 58
years. A preliminary analysis of the data indicated that
the average HgbA1c decreased from 10.3 to 8.5, with 9
patients attaining glycemic control (defined as HgbA1c 
8.0) after one year of enrollment. Additionally, average
blood pressure decreased from 152/80 to 136/73. The av-
erage annual cost per patient for diabetes-related care
was $3,090 pre-enrollment and $4,760 post-enrollment.
A marginal cost-effectiveness ratio, in terms of cost to
number of patients attaining glycemic control, was calcu-
lated. The added cost for glycemic control of one patient
was $186. CONCLUSIONS: An analysis of short-term
outcomes demonstrated the cost-effectiveness of a diabe-
tes care clinic. By maintaining tight glycemic and blood
pressure control, diabetic complications can be reduced
with significant savings to the health plan.
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THE COST OF NEW ONSET DIABETES 
MELLITUS AMONG US RENAL
TRANSPLANT RECIPIENTS
Woodward RS1, Schnitzler MA1, Lowell JA1, Haider S2, 
Brennan DC1
1Washington University, St. Louis, MO, USA; 2Pfizer, Inc, 
Groton, CT, USA
OBJECTIVES: Immunosuppressive medications are asso-
ciated with increased diabetes among kidney transplant
recipients. We used data from the USRDS database to es-
timate the incidence and the average cost to Medicare of
new onset diabetes Mellitus (NODM). METHODS: The
USRDS database merges the UNOS renal transplant reg-
istry with Medicare billing and payment records. The
USRDS registry recorded 9,541 single-organ, first, kidney
transplants in 1996; 5,987 (63%) of these were not dia-
betic at transplantation. For the 4,515 (75% of 5,987)
patients with Medicare claims, we merged all Medicare
institutional and physician supplier claims records from
1996 through 1997 with the clinical information from
UNOS. We classified patients as newly diabetic if any
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ICD-9 diabetes diagnosis (250.00 to 250.79) occurred
within one year of the patient’s transplant. We then used
a Kaplan-Meier-style non-parametric calculation to esti-
mate the average accumulated costs for patients with and
without NODM. RESULTS: Among the 4,515 trans-
plant recipients studied, 621 (13.7%) reported diabetes
diagnoses within the first year post-transplant. By the end
of the first post-transplant year, Medicare had paid
$35,288 for each non-diabetic recipient and an extra
$17,614 (P  0.001) for each of the NODM recipients.
By two years post-transplant, Medicare had paid an aver-
age $46,869 for each of the non-diabetic recipients and
an extra $26,032 for each of the NODM recipients (P 
0.001). CONCLUSIONS: Our 13.7% NODM exceeds
the 2% to 5% previously reported, and the extra
$26,032 is 55.5% above what Medicare paid for recipi-
ents without NODM. New immunosuppressives unasso-
ciated with NODM may generate substantial savings
worldwide.
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ECONOMIC OUTCOMES OF DIABETES AMONG 
AN EMPLOYED POPULATION
Leong SA1, Summers KH2, Birnbaum HG1, Kemner JE2,
Lentz EC1, Greenberg PE1
1Analysis Group/Economics, Cambridge, MA, USA; 2Eli Lilly and 
Company, Indianapolis, IN, USA
OBJECTIVES: The two major types of diabetes, Type I
and Type II diabetes, can have life-threatening complica-
tions, which often lead to significant adverse economic
consequences. This study investigates the extent to which
Type I and Type II diabetes impose significant financial
burdens on an employer METHODS: The data source is
a rich administrative claims database from a national,
Fortune 100 manufacturer. It includes all medical, phar-
maceutical, and disability claims for employees, spouses,
dependents, and retirees (n  100,000). The diabetes re-
search sample consists of individuals with at least two
medical and/or disability claims for diabetes or at least
one prescription drug claim for a hypoglycemic agent.
Resource utilization by diabetes patients, who are identi-
fied as either Type I or Type II diabetics, is contrasted
with that of matched samples from the employer’s overall
beneficiary population. RESULTS: Direct (medical and
pharmaceutical) and indirect (disability and sporadic ab-
senteeism) costs of Type I and Type II diabetes are ana-
lyzed. The total average per capita annual costs are
$2,612 for the Matched Type I Control sample compared
to $9,397 for Type I diabetics, and $3,432 for the
Matched Type II Control sample compared to $7,639 for
Type II diabetics. While Type I diabetics cost the em-
ployer more than Type II diabetics on average, the cost of
Type II diabetes patients, who were prescribed insulin,
exceeds the cost of Type I diabetes patients. Also, while
the costs of both types of diabetes are relatively high, less
than 50% of total medical costs for these patients are for
the treatment of diabetes or related co-morbid condi-
tions. CONCLUSIONS: Diabetes adds a significant fi-
nancial burden on the employer. The resources used by
both types of diabetics are substantial, not only for the
treatment of diabetes, but also for the treatment of re-
lated co-morbid conditions, as well as other conditions.
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A PHARMACOECONOMIC ANALYSIS OF 
WEIGHT-REDUCTION THERAPY IN A 
HYPOTHETICAL COHORT OF OBESE CHINESE 
PATIENTS WITH IMPAIRED
GLUCOSE TOLERANCE
Lee KK, You JH, Ho SS, Leung WY, Thomas G, Chan TY, 
Critchley J
The Chinese University of Hong Kong, Hong Kong, China
OBJECTIVES: To conduct a pharmacoeconomic analysis
to estimate the potential cost avoidance due to reduced
rate of incidence of diabetes after weight-reduction ther-
apy in obese Chinese patients with impaired glucose tol-
erance (IGT). METHODS: The incidence of IGT-to-dia-
betes mellitus (DM) conversion of two hypothetical
cohorts of obese Chinese patients with IGT, either man-
aged with diet control (n  100) or diet control plus or-
listat (n  100), were projected over a two-year period.
The probabilities of IGT-to-DM progression in the or-
listat plus diet group and the diet only group were esti-
mated from a published study in a non-Chinese and a
westernized Chinese population, respectively. Direct medical
costs of management of type 2 diabetes were estimated
from a public budget perspective. RESULTS: The esti-
mated rates of IGT-to-DM conversion were 1.9% for the
orlistat plus diet group and 8% for the diet only group.
The total costs of DM management at the end of the first
and second years were estimated to be HK$8,187 and
HK$23,390 ($HK 7.8  $US 1) for the orlistat group. In
the diet only group, the costs of DM management were
HK$34,469 in year one and HK$100,123 in year two.
The cost avoidance associated with orlistat therapy were
calculated to be HK$26,282 and HK$75,092 per 100 pa-
tients at the end of the first and second years, respec-
tively. CONCLUSIONS: Results of the present study sug-
gest positive economic impacts of weight-reduction therapy
in a hypothetical Chinese population with IGT in the pre-
vention of type 2 diabetes.
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OPTIMIZATION OF DIABETES MANAGEMENT 
IN GERMANY USING A COMPUTER BASED 
OUTCOME PROGNOSES MODEL
Brandt A, Gozzoli V, Palmer A, Weiss C, Neeser K, 
Schramm W
Institute for Medical Informatics and Biostatistics (IMIB), Riehen, 
Switzerland
OBJECTIVES: Optimization of type 2 diabetes interven-
tion strategies in Germany based on stepwise prognoses
